Dyne Therapeutics (DYN) Price & Analysis

Compare

362 Followers

DYN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.36 - $47.45

Previous CloseN/A

Volume117.44K

Average Volume (3M)2.93M

Market Cap

$1.43B

Enterprise Value$521.22M

Total Cash (Recent Filing)$683.92M

Total Debt (Recent Filing)$22.26M

Price to Earnings (P/E)―

Beta2.17

Next Earnings

Oct 30, 2025

EPS Estimate

-0.85

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding142,263,730

10 Day Avg. Volume2,296,431

30 Day Avg. Volume2,928,633

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.36

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.19

Forecast

1Y Price Target

$32.18

Price Target Upside207.35% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Financial StabilityManagement's recent financing extended DYN's runway into 3Q27, enabling derisking of the DM1 program and commercialization of the DMD program.

Regulatory SupportThe FDA granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with Duchenne muscular dystrophy, highlighting unmet need and FDA support.

Therapeutic EfficacyDYNE-251 delivered robust muscle content-adjusted dystrophin expression and sustained effect on functional outcomes, which can enable BLA submission for accelerated approval.

Bears Say

Competitive PressurePotential DYNE-101 AA in 2027 could reduce the development gap versus competitor Del-desiran, enabling easier comparison of treatment effects.

Investor ConcernsThe primary endpoint change to vHOT from CASI-22 could trigger some investor questions or concerns.

Regulatory ChallengesThe main investor debate revolves around potential regulatory complications caused by DYNE-101 competitor Del-desiran being evaluated in a full approval pathway.

Dyne Therapeutics News

Dyne Therapeutics trading resumes

11:24 EDT Dyne Therapeutics (DYN) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

7h ago

DYN

Dyne Therapeutics trading halted, volatility trading pause

11:19 EDT Dyne Therapeutics (DYN) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

8h ago

DYN

Dyne Therapeutics price target lowered to $13 from $34 at Oppenheimer

Oppenheimer lowered the firm’s price target on Dyne Therapeutics (DYN) to $13 from $34 and keeps an Outperform...

11h ago

DYN

Dyne Therapeutics announces FDA BTD to DYNE-251

Dyne Therapeutics (DYN) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD,...

2d ago

DYN

Dyne Therapeutics price target lowered to $31 from $37 at Raymond James

Raymond James analyst Martin Auster lowered the firm’s price target on Dyne Therapeutics (DYN) to $31 from $37...

8d ago

DYN

Dyne Therapeutics price target lowered to $23 from $25 at RBC Capital

RBC Capital analyst Luca Issi lowered the firm’s price target on Dyne Therapeutics (DYN) to $23 from $25...

8d ago

DYN

Dyne Therapeutics reports Q2 EPS (97c), consensus (93c)

“This quarter we made significant progress on our clinical and regulatory plans for our DM1 and DMD investigational...

9d ago

DYN

Dyne Therapeutics expects cash to fund operations into Q3 of 2027

Dyne expects that its existing cash, cash equivalents and marketable securities, including the net proceeds from the July...

9d ago

DYN

Dyne Therapeutics CEO buys $911K in common stock

In a regulatory filing, Dyne Therapeutics (DYN) disclosed that its CEO John Cox bought 100K shares of common...

22d ago

DYN

Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dyne Therapeutics (DYN) to $41 from $46...

26d ago

DYN

Dyne Therapeutics: Promising Advancements and FDA Support Drive Buy Rating

Analyst Michael Ulz of Morgan Stanley reiterated a Buy rating on Dyne Therapeutics, retaining the price target of...

2d ago

DYN

Dyne Therapeutics Gains FDA Breakthrough Designation for DYNE-251

Dyne Therapeutics ( ($DYN) ) just unveiled an update. On August 4, 2025, Dyne Therapeutics announced that the...

2d ago

DYN

Dyne Therapeutics: Strategic Advancements and Financial Stability Drive Buy Rating

Kostas Biliouris, an analyst from BMO Capital, maintained the Buy rating on Dyne Therapeutics. The associated price target...

7d ago

DYN

Dyne Therapeutics: Promising Clinical Developments and Strategic Positioning Drive Buy Rating

H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on Dyne Therapeutics today and set a price target...

9d ago

DYN

DYN FAQ

What was Dyne Therapeutics’s price range in the past 12 months?

Dyne Therapeutics lowest stock price was $6.36 and its highest was $47.45 in the past 12 months.

What is Dyne Therapeutics’s market cap?

Dyne Therapeutics’s market cap is $1.43B.

When is Dyne Therapeutics’s upcoming earnings report date?

Dyne Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 85 days.

How were Dyne Therapeutics’s earnings last quarter?

Dyne Therapeutics released its earnings results on Jul 28, 2025. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.942 by -$0.028.

Is Dyne Therapeutics overvalued?

According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dyne Therapeutics pay dividends?

Dyne Therapeutics does not currently pay dividends.

What is Dyne Therapeutics’s EPS estimate?

Dyne Therapeutics’s EPS estimate is -0.85.

How many shares outstanding does Dyne Therapeutics have?

Dyne Therapeutics has 142,263,730 shares outstanding.

What happened to Dyne Therapeutics’s price movement after its last earnings report?

Dyne Therapeutics reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.942. Following the earnings report the stock price went down -1.182%.

Which hedge fund is a major shareholder of Dyne Therapeutics?

Currently, no hedge funds are holding shares in DYN

Dyne Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-61.32%

Trailing 12-Months

Asset Growth

-11.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dyne Therapeutics

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Dyne Therapeutics (DYN) Earnings & Revenues

Historic Earnings Reports

DYN Stock 12 Month Forecast

Average Price Target

$32.18

▲(207.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.05,13.123076923076924,16.196153846153848,19.26923076923077,22.342307692307692,25.415384615384617,28.48846153846154,31.561538461538465,34.63461538461539,37.70769230769231,40.78076923076924,43.85384615384616,46.926923076923075,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.05,11.752307692307692,13.454615384615385,15.156923076923078,16.85923076923077,18.56153846153846,20.263846153846153,21.966153846153848,23.66846153846154,25.37076923076923,27.073076923076922,28.775384615384617,30.47769230769231,{"y":32.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.05,9.96923076923077,9.88846153846154,9.807692307692308,9.726923076923077,9.646153846153847,9.565384615384616,9.484615384615385,9.403846153846153,9.323076923076924,9.242307692307692,9.161538461538461,9.080769230769231,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.08,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >